-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

Benzinga·09/03/2026 14:21:58
Listen to the news
Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.